Treatment Sequencing Decisions in ALK+ NSCLC
This video segment examines therapeutic strategies for managing disease progression on lorlatinib in ALK-positive metastatic NSCLC, including decision-making considerations and scenarios where switching to lorlatinib from another ALK inhibitor may be beneficial.
Video content above is prompted by the following:
- If this patient were to experience disease progression on lorlatinib, what would be your next therapeutic approach and why?
- What considerations would guide your decision-making process?
- If this patient had started on a different ALK inhibitor, when/why might you consider a switch to lorlatinib?
Recent Videos
